Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangjin Shuangshen
- Development stage
- Preclinical
- Lead developer
- Zhejiang Chinese Medical University
- Administration
- Oral
01
Overview
Huangjin Shuangshen is a traditional Chinese medicine (TCM) formulation, specifically prepared as granules, currently under investigation for its therapeutic potential. It is being studied for the treatment of gastric cancer and for managing anxiety and depression following coronary stent implantation. The drug is administered orally.
- Brand names
- Huangjin Shuangshen Granules
- Other names
- Huangjin Shuangshen GranulesHuangjinshuangshenjiawei Granules黄金双参加味颗粒口服黄金双参加味颗粒
02
Targets
ACE (Angiotensin Converting Enzyme)CCL2 (C-C motif chemokine 2)CXCL10 (C-X-C Motif Chemokine Ligand 10)IFNG (Interferon gamma)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Huangjin Shuangshen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Huangjin Shuangshen.